secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001437749-23-014365
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Q1 2023: cash $103.9M, no debt; Phase 2 trials initiated/expanded
------------------------------------------------------------------------

- Ended Q1 2023 with $103.9M cash and cash equivalents, zero debt.
- Operating expenses $7.1M (up 50% YoY); R&D $3.5M (+134%) on (Z)-endoxifen trials.
- Initiated Phase 2 EVANGELINE and new I-SPY 2 arm for (Z)-endoxifen in ER+/HER2- breast cancer.
- Full enrollment of Phase 2 KARISMA breast density study expected by end of 2023.
- US patent granted for (Z)-endoxifen enteric capsule (No. 11,572,334).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923014365/0001437749-23-014365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923014365/atos20230508_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-014365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer